Jazz Pharmaceuticals plc — Director's Dealing 2018

Oct 17, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2018-10-15

Reporting Person: Young Matthew P. (EVP & CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-10-15	Ordinary Shares	S	700	$158.0828	Disposed	32768	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $158.0762 to $158.0916. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.